Abstract
The Role of Sacubitril-Valsartan in Post-Acute Myocardial Infarction (RSV-PAMI) Trial: Preliminary Results
Cardiovascular revascularization medicine, Vol.28, pp.S13-S14
07/2021
DOI: 10.1016/j.carrev.2021.06.032
Abstract
Background: So far, there are no data available about the effect of de novo use of sacubitril/valsartan (SAC/VAL) in post-acute myocardial infarction (AMI) except in animal experimental models. The aim of this trial is to evaluate the effects of the use of SAC/VAL in AMI in comparison to the conventional therapy in treatment of post-AMI patients with reduced left ventricular (LV) systolic function.
Methods: The RSV-PAMI (The role of Sacubitril-Valsartan in Post-Acute Myocardial Infarction NCT03893435) is a randomized open-label interventional clinical trial that is currently recruiting 200 patients with revascularized ST-elevation myocardial infarction (STEMI) and reduced LV systolic function, assessed by transthoracic echocardiography (TTE) and assigned to treatment with SAC/VAL or conventional angiotensin receptor blockers. The primary outcomes are in-hospital, major adverse cardiovascular and cerebrovascular events (MACCE) at 6 months, and left ventricular ejection fraction (LVEF) assessed by TTE during hospital stay at 3 and 6 months.
Results: Currently, we have recruited 90 AMI patients and placed them into 2 randomized groups, each containing45 patients, with results highlighted in Table 1.
Conclusion: Based on these preliminary results, there was no significant difference between SAC/VAL and VAL as regards LVEF at 3 and 6 months, in-hospital and 6 months MAACE.
Details
- Title: Subtitle
- The Role of Sacubitril-Valsartan in Post-Acute Myocardial Infarction (RSV-PAMI) Trial: Preliminary Results
- Creators
- Mahmoud Abdelnabi - Alexandria UniversityYehia Saleh - Houston MethodistHaitham Badran - Ain Shams UniversityAbdallah Almaghraby - Alexandria University
- Resource Type
- Abstract
- Publication Details
- Cardiovascular revascularization medicine, Vol.28, pp.S13-S14
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.carrev.2021.06.032
- ISSN
- 1553-8389
- eISSN
- 1878-0938
- Language
- English
- Date published
- 07/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984757273102771
Metrics
1 Record Views